Mayo Clinic Laboratories > Hematology > Lymphoid and plasma cell neoplasms testing

Lymphoid and plasma cell neoplasms testing: Tailor disease management

Synthesizing scientific discovery with leading-edge innovation

Among the more rare and complex hematologic malignancies are certain types of plasma cell, histiocytic, and lymphoid neoplasms. With diverse clinical presentations, these cancers can be challenging to correctly identify. Because certain subtypes are more aggressive and difficult to treat, accurate diagnosis is vital to optimize treatment selection.

Molecular profiling of hematologic cancers is an evolving approach that allows in-depth understanding and classification of the specific cancer type. Understanding the genetic intricacies of a patient’s condition can clarify diagnosis, inform prognosis, and help physicians personalize patient care.

46

46 genes included in our comprehensive B-cell lymphoma panel

22

22 genes included in our comprehensive T-cell lymphoma panel

25

25 genes included in our chronic lymphoid panel

26

26 genes included in our plasma-cell neoplasms panel

8

8 genes included in our histiocytic neoplasmS panel

B-cell lymphoma B-cell lymphoma
B-cell lymphoma

Our B-cell lymphoma testing includes next-generation sequencing and FISH testing to identify genetic abnormalities associated with B-cell lymphoma subtypes.

Histiocytic neoplasms Histiocytic neoplasms
Histiocytic neoplasms

Our next-generation sequencing panel for histiocytic neoplasms was carefully curated to include select genes with high clinical value to characterize the disease and provide insight into the differential diagnosis of and therapeutic options for these rare tumors.

Plasma cell neoplasms Plasma cell neoplasms
Plasma cell neoplasms

Our unique next-generation sequencing panel evaluates 26 genes associated with plasma cell neoplasms and can provide insights that clarify diagnosis and prognosis, assist with disease monitoring, and guide treatment selection.

T-cell lymphoma T-cell lymphoma
T-cell lymphoma

We offer next-generation sequencing and comprehensive fluorescence in situ hybridization (FISH) panels, as well as extensive immunohistochemistry (IHC) offerings, to diagnose and monitor T-cell lymphoma.

Precise, personal, powerful

When deemed clinically necessary, next-generation sequencing (NGS) can supplement standard of care testing to refine diagnosis. Our full menu of MayoComplete NGS panels for lymphoid, histiocytic, and plasma cell neoplasms equips physicians with the right tools to understand the distinctive genetic features of their patients’ cancer, empowering them to tailor disease management for some of the most serious hematologic disorders. Our testing:

  • Provides diagnostic, prognostic, and therapeutic insights to direct treatment selection from an array of options, including the latest targeted and immune therapies.
  • Identifies distinct lymphoma subtypes to guide prognosis and treatment personalization for improved efficacy.
  • Is developed by and with the expertise of Mayo Clinic geneticists, pathologists, oncologists, hematologists, and variant scientists to align with guidelines of clinical significance.

Building trust with unmatched expertise  

Leveraging the knowledge of industry-leading scientists and physicians, Mayo Clinic Laboratories offers solutions for understanding the most challenging hematologic cancers. Our integration with the clinical hematology practice at Mayo Clinic fosters the development of clinically significant assays that deliver precise, detailed answers to enhance patient care.

“Molecular classification with targeted next-generation sequencing panels is relatively new to this space. We wanted to bring up smaller panels and focus on those genetic targets that are going to have the most clinical relevance, and that is what we honed in on.”

Cody Artymiuk, senior developer in the Division of Hematopathology at Mayo Clinic

Highly curated, clinically meaningful testing

Mayo IDTest nameGenes included
NGCLNMayoComplete Chronic Lymphoid Neoplasms, Next-Generation Sequencing, Varies

Evaluates a 25-gene subset of NGBCL		ATM, BCL2, BIRC3, BRAF, BTG1, BTK, CCND1, CDKN2A, CXCR4, DDX3X, EZH2, FBXW7, KLF2, KRAS, MAP2K1, MYD88, NOTCH1, NOTCH2, NRAS, PIK3CA, PLCG2, SF3B1, TNFAIP3, TP53, and XPO1
NGBCLMayoComplete B-Cell Lymphoma, Next-Generation Sequencing, Varies  

Evaluates 46 genes		ARAF, ARID1A, ATM, B2M, BCL2, BIRC3, BRAF, BTG1, BTK, CARD11, CCND1, CCND3, CD79A, CD79B, CDKN2A, CREBBP, CSF1R, CXCR4, DDX3X, EP300, EZH2, FBXW7, FOXO1, ID3, KLF2, KMT2D, KRAS, MAP2K1, MEF2B, MYD88, NOTCH1, NOTCH2, NRAS, NSD2, PIK3CA, PIM1, PLCG2, PRDM1, PTEN, SF3B1, STAT6, TCF3, TNFAIP3, TNFRSF14, TP53, and XPO1
NGTCLMayoComplete T-Cell Lymphoma, Next-Generation Sequencing, Varies  

Evaluates 22 genes		ARID1B, CCR4, CXCR4, DDX3X, DNMT3A, EZH2, FYN, IDH1, IDH2, JAK1, JAK3, KMT2D, KRAS, MSC, NOTCH1, NRAS, PLCG1, RHOA, STAT3, STAT5B, TET2, and TP53
NGHISMayoComplete Histiocytic Neoplasms, Next-Generation Sequencing, Varies

Evaluates 8 genes		ARAF, BRAF, CSF1R, KRAS, MAP2K1, NRAS, PIK3CA, PTEN
NGPCMMayoComplete Plasma Cell Myeloma, Next-Generation Sequencing, Varies  

Evaluates 26 genes		BIRC3, BRAF, CCND1, CDKN2A, CRBN, CUL4A, CUL4B, CXCR4, DIS3, EGFR, IDH1, IDH2, IKZF1, IKZF3, KRAS, MYC, MYD88, NRAS, NSD2, PIK3CA, PIM1, STAT3, TENT5C, TP53, TRAF3, and XBP1

Let us help you better define your patient’s diagnosis, prognosis, and therapeutic approach.

Learn more about our complete menu of advanced molecular testing for lymphoid, histiocytic, and plasma cell neoplasms. Schedule a time to discuss with one of our clinical specialists.

Resources
Learn more The Hematology, Oncology, and Hereditary test selection guide
Learn more Clinical Validation of a Targeted Next-Generation Sequencing Panel for Lymphoid Malignancies
Learn more Mayo Clinic-led research on identification of patients affected by follicular lymphoma and diffuse large B-cell lymphoma with BCL2 and IRF4 rearrangements using NGS testing